Albiglutide is primarily used in the management of type 2 diabetes. It functions as a glucagon-like peptide-1 (GLP-1) receptor agonist, helping to regulate blood sugar levels by enhancing insulin secretion in response to meals and reducing excessive glucagon release. This medication is particularly beneficial for patients who struggle to achieve adequate glycemic control through diet, exercise, and other oral antidiabetic agents. It is administered via subcutaneous injection, typically once weekly, offering convenience and improved adherence for patients. Additionally, albiglutide has been associated with weight loss or weight stabilization, which is advantageous for many individuals with type 2 diabetes who are often overweight or obese. Its use may also contribute to a lower risk of hypoglycemia compared to some other diabetes treatments, making it a safer option for certain patient populations.